<DOC>
	<DOCNO>NCT00704405</DOCNO>
	<brief_summary>The purpose study test safety , tolerability , efficacy 4 regimen Vaniprevir + Peg-IFN Ribavirin compare Placebo ( PBO ) + Peg-IFN/RBV . The primary hypothesis Vaniprevir well tolerate , Vaniprevir 600 mg twice daily ( b.i.d . ) superior control regimen percentage non-cirrhotic ( NC ) participant achieve undetectable HCV ribonucleic acid ( RNA ) 24 week end study therapy ( SVR24 ) .</brief_summary>
	<brief_title>Safety Efficacy Vaniprevir ( MK-7009 ) With Pegylated Interferon ( Peg-IFN ) Ribavirin ( RBV ) Treatment-Experienced Hepatitis C Virus ( HCV ) Participants ( MK-7009-009 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : Has chronic HCV genotype 1 infection Is treatmentexperienced For noncirrhotic population , liver biopsy without evidence cirrhosis hepatocellular carcinoma ; cirrhotic population , liver biopsy evidence cirrhosis without evidence hepatocellular carcinoma . Exclusion criterion : Has tolerate previous course pegIFN RBV Is unlikely tolerate least 24 week continuous therapy PegIFN RBV Is coinfected Human Immunodeficiency Virus ( HIV ) and/or hepatitis B Consumes excessive amount alcohol Has history drug alcohol abuse If female , participant pregnant breastfeeding Has clinical trail investigational drug last 30 day Has use IFN/PegIFN RBV last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>